Tarix Pharmaceuticals: Clinical Trials

4 terminated, 3 completed, 3 withdrawn, 1 active not recruiting. 6 Phase 2, 4 Phase 1, 1 Not applicable.

By phase and status

Phase	Trials	Status
Phase 2	6	Withdrawn 3, Completed 2, Terminated 1
Phase 1	4	Terminated 3, Completed 1
Not applicable	1	Active not recruiting 1

Follow Tarix Pharmaceuticals: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer 89Zr-TLX250 - Triple Negative Breast Cancer	Phase 2	Completed	Institut Cancerologie de l'Ouest	12	2021-09-21	2026-07-20
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation TXA127 - Hematologic Malignancies	Phase 2	Withdrawn	Tarix Pharmaceuticals		2013-12-01	2016-08-31
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation TXA127 - Hematologic Malignancies	Phase 2	Withdrawn	Tarix Pharmaceuticals		2013-12-01	2016-08-31
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma 124IcG250 - Renal Cancer	Not applicable	Active not recruiting	Memorial Sloan Kettering Cancer Center	17	2012-04-01	2026-07-08
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation TXA127 - Cord Blood Transplant, Hematologic Malignancy	Phase 2	Withdrawn	Tarix Pharmaceuticals		2012-03-01	2016-08-31
Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia TXA127 - Myelodysplastic Syndrome (MDS)	Phase 1	Terminated	Tarix Pharmaceuticals	2	2011-04-01	2016-08-31
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day - Double Cord Blood Transplant, Acute Myelogenous Leukemia	Phase 1	Terminated	Tarix Pharmaceuticals	20	2011-01-01	2020-12-08
Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients TXA127, Placebo - Lymphoma, Non-Hodgkin, Hodgkin Disease	Phase 2	Terminated	Tarix Pharmaceuticals	75	2010-06-01	2020-12-08
Safety and Efficacy of TXA127 and Neupogen to Increase Peripheral Blood Stem Cells (PBSCs) TXA127, Neupogen (filgrastim) - Miscellaneous Peripheral Blood Cell Abnormalities	Phase 1	Completed	Tarix Pharmaceuticals	18	2009-12-01	2016-08-31
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer TXA127, Placebo - Thrombocytopenia, Neutropenia	Phase 2	Completed	Tarix Pharmaceuticals	34	2008-10-01	2017-11-13
Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy Angiotensin 1-7 - HIV Infections	Phase 1	Terminated	US Biotest, Inc.	13	2008-09-01	2012-02-29

Conditions studied

Mucositis (4)  ·  Hematologic Neoplasms (3)  ·  Hodgkin Disease (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Myelodysplastic Syndromes (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Adenocarcinoma, Clear Cell (1)  ·  Anemia (1)  ·  Cytopenia (1)  ·  Graft vs Host Disease (1)  ·  HIV Infections (1)  ·  Kidney Neoplasms (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)

Interventions

angiotensin I (1-7) (9)  ·  Filgrastim (1)

Countries

United States (10)  ·  France (1)

Top investigators

Darren Feldman, MD (1)  ·  Edmund K Waller, MD,PhD,FACP (1)  ·  Joanne Kurtzberg, MD (1)  ·  Kristin Page, MD (1)  ·  Mary J Laughlin, MD (1)  ·  Michael Schuster, MD (1)  ·  Robert A Larsen, MD (1)  ·  Uday R Popat, MD (1)

Results publications

PMID 41174094